Luseogliflozin: Difference between revisions

From WikiMD's Wellness Encyclopedia

CSV import
 
CSV import
 
Line 1: Line 1:
'''Luseogliflozin''' is a [[Sodium-glucose cotransporter 2 inhibitors|SGLT2 inhibitor]] used in the treatment of [[Type 2 diabetes]]. It is marketed in Japan by Taisho Pharmaceutical.
{{Short description|An article about the antidiabetic medication Luseogliflozin}}


== Mechanism of Action ==
==Luseogliflozin==
Luseogliflozin works by inhibiting [[Sodium-glucose cotransporter 2|SGLT2]], a protein in the kidneys that reabsorbs glucose into the bloodstream. By blocking this protein, luseogliflozin causes excess glucose to be eliminated in the urine, thereby lowering blood glucose levels.
[[File:Luseogliflozin_structure.svg|thumb|right|Chemical structure of Luseogliflozin]]
'''Luseogliflozin''' is an oral [[antidiabetic drug]] belonging to the class of [[sodium-glucose co-transporter 2 inhibitors]] (SGLT2 inhibitors). It is used in the management of [[type 2 diabetes mellitus]] to improve glycemic control in adults.


== Indications ==
==Mechanism of Action==
Luseogliflozin is indicated for the treatment of adults with [[Type 2 diabetes]] who are not adequately controlled on diet and exercise alone. It may be used as monotherapy or in combination with other antidiabetic medications.
Luseogliflozin works by inhibiting the [[sodium-glucose co-transporter 2]] (SGLT2) in the [[proximal tubule]] of the [[nephron]] in the [[kidney]]. This inhibition reduces the reabsorption of [[glucose]] from the [[glomerular filtrate]] back into the bloodstream, leading to increased urinary glucose excretion and a reduction in blood glucose levels.


== Side Effects ==
==Pharmacokinetics==
Common side effects of luseogliflozin include urinary tract infections, increased urination, and genital fungal infections. Rare but serious side effects include ketoacidosis, kidney injury, and severe allergic reactions.
Luseogliflozin is administered orally and is absorbed in the [[gastrointestinal tract]]. It has a high bioavailability and is metabolized primarily in the [[liver]]. The drug and its metabolites are excreted via the [[urine]] and [[feces]].


== Contraindications ==
==Clinical Use==
Luseogliflozin is contraindicated in patients with severe renal impairment, end-stage renal disease, or dialysis. It is also contraindicated in patients with a history of hypersensitivity to luseogliflozin or any of its components.
Luseogliflozin is indicated for the treatment of [[type 2 diabetes mellitus]] in adults. It is often used in combination with other antidiabetic medications such as [[metformin]], [[sulfonylureas]], or [[insulin]] to achieve better glycemic control.


== Interactions ==
==Side Effects==
Luseogliflozin may interact with other medications, including diuretics, insulin, and other antidiabetic drugs. Patients should inform their healthcare provider of all medications they are currently taking.
Common side effects of Luseogliflozin include [[urinary tract infections]], [[genital mycotic infections]], and increased urination. It may also cause [[hypotension]] due to its diuretic effect. Rarely, it can lead to [[ketoacidosis]] and [[acute kidney injury]].


== See Also ==
==Contraindications==
* [[Sodium-glucose cotransporter 2 inhibitors]]
Luseogliflozin is contraindicated in patients with severe [[renal impairment]], [[end-stage renal disease]], or those on [[dialysis]]. It should not be used in patients with a history of serious hypersensitivity to the drug.
* [[Type 2 diabetes]]
* [[Antidiabetic medication]]


[[Category:Drugs]]
==Related pages==
[[Category:Diabetes]]
* [[Type 2 diabetes mellitus]]
[[Category:Endocrinology]]
* [[Sodium-glucose co-transporter 2 inhibitors]]
{{stub}}
* [[Antidiabetic drugs]]
 
[[Category:Antidiabetic drugs]]
[[Category:SGLT2 inhibitors]]

Latest revision as of 06:26, 16 February 2025

An article about the antidiabetic medication Luseogliflozin


Luseogliflozin[edit]

Chemical structure of Luseogliflozin

Luseogliflozin is an oral antidiabetic drug belonging to the class of sodium-glucose co-transporter 2 inhibitors (SGLT2 inhibitors). It is used in the management of type 2 diabetes mellitus to improve glycemic control in adults.

Mechanism of Action[edit]

Luseogliflozin works by inhibiting the sodium-glucose co-transporter 2 (SGLT2) in the proximal tubule of the nephron in the kidney. This inhibition reduces the reabsorption of glucose from the glomerular filtrate back into the bloodstream, leading to increased urinary glucose excretion and a reduction in blood glucose levels.

Pharmacokinetics[edit]

Luseogliflozin is administered orally and is absorbed in the gastrointestinal tract. It has a high bioavailability and is metabolized primarily in the liver. The drug and its metabolites are excreted via the urine and feces.

Clinical Use[edit]

Luseogliflozin is indicated for the treatment of type 2 diabetes mellitus in adults. It is often used in combination with other antidiabetic medications such as metformin, sulfonylureas, or insulin to achieve better glycemic control.

Side Effects[edit]

Common side effects of Luseogliflozin include urinary tract infections, genital mycotic infections, and increased urination. It may also cause hypotension due to its diuretic effect. Rarely, it can lead to ketoacidosis and acute kidney injury.

Contraindications[edit]

Luseogliflozin is contraindicated in patients with severe renal impairment, end-stage renal disease, or those on dialysis. It should not be used in patients with a history of serious hypersensitivity to the drug.

Related pages[edit]